FDA Approves Daratumumab-Based Quadruplet Regimen for Transplant-Eligible Myeloma
The U.S. Food and Drug Administration (FDA) has approved daratumumab, in combination with bortezomib, thalidomide, and dexamethasone, to treat adult patients with newly diagnosed...
More Options, More Questions: Debating the Optimal Frontline Regimen for Multiple Myeloma
As part of the 2019 ASH Meeting on Hematologic Malignancies held September 6-7 in Chicago, experts were invited to discuss challenging patient care questions,...
From ASH Meeting on Hematologic Malignancies: How would you treat relapsed/refractory myeloma after transplant?
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
European Commission Approves Elotuzumab Triplet for Multiple Myeloma
The European Commission (EC) has approved elotuzumab plus pomalidomide and low-dose dexamethasone (EPd) to treat relapsed and refractory multiple myeloma in adult patients who...
Isatuximab Combination Improves Progression-Free Survival in Pretreated Myeloma
The combination of isatuximab and pomalidomide plus dexamethasone (Pd) extended progression-free survival (PFS) to 11.5 months in patients with relapsed/refractory multiple myeloma (MM) –...
Daratumumab Combination Induces High Response Rates in AL Amyloidosis
In one-year follow-up data from the phase III ANDROMEDA trial, the combination of subcutaneous daratumumab with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) led to high...
AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma
In updated results from the first-in-human study of the bispecific T-cell engager (BITE) AMG 420, the agent continued to demonstrate clinical activity in patients...
Equal Access to Treatment Erases Difference in Outcomes Between White and African American Patients...
If African American patients with multiple myeloma (MM) are given equal access to treatments, they have outcomes that are as good as or better...
Daratumumab Combination Extends Progression-Free Survival for Transplant-Ineligible Myeloma
In patients with newly diagnosed multiple myeloma (MM) who were ineligible for autologous hematopoietic cell transplantation (AHCT), adding daratumumab to a regimen of lenalidomide...
FDA Grants Selinexor Accelerated Approval Despite Concerns With Trial Data
The U.S. Food and Drug Administration (FDA) granted accelerated approval to for selinexor, an oral selective inhibitor of nuclear export (SINE), for patients with...
Current Issue
October 2019, Volume 5, Issue 12
This issue highlights the unintended consequences of fighting the nation’s opioid epidemic, considers the optimal frontline regimen for myeloma, and more.
